Astellas Pharma says a drug product manufacturing facility in Tralee, Ireland will strengthen its internal supply chain. According to the firm, the investment worth over €330 million ($351 million) will bolster capacity and capabilities for aseptic drug products. Additionally, the facility will support stable manufacturing for global supply and advance the development and commercialization of antibody drugs and various other products. “It will enhance our in-house production capability and strengthen the manufacturing and supply chain from development to commercialization. This…